The modified mRNA vaccine protects immunocompromised AG129 mice from lethal challenge and multi-tissue infection by Zika virus.

ABSTRACT: The multiple epidemics of Zika virus (ZIKV) posed a substantial threat to public health. Clinical evidence suggests that ZIKV could break through the blood-brain, blood-placenta, and blood-testis barriers, leading to severe outcomes such as congenital malformations in newborns and Guillain-Barré syndrome in adults. Currently, there are no specific treatments for ZIKV infection. To address the antibody-dependent enhancement (ADE) of dengue virus (DENV) infection induced by ZIKV vaccination, we designed two modified prM-E RNAs (ZA and ZB) with specific mutations either shielding or disrupting the conserved fusion-loop epitope in the E protein. Then, we chose the mRNA-LNP vaccine platform to evaluate the safety and efficacy. After prime-boost immunization, ZA vaccine could induce high levels

SUBMITTER: Yan Y 

PROVIDER: S-EPMC12451962 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature